Suppr超能文献

[1992年的袢利尿剂。作用机制及当前治疗原则]

[Loop-diuretics anno 1992. Mechanisms of effect and current therapeutic principles].

作者信息

Berg K J

机构信息

Seksjon for nyresykdommer Medisinsk avdeling B Rikshospitalet, Oslo.

出版信息

Tidsskr Nor Laegeforen. 1992 Feb 20;112(5):656-8.

PMID:1557735
Abstract

Loop-diuretics inhibit the Na+/K+/2Cl(-) -cotransport system in the thick ascending loop of Henle, and are the most potent of the diuretic agents. They also increase production of prostaglandins and, when given intravenously, reduce pulmonary capillary pressure. The clinical effects, and side effects, of loop diuretics are reviewed. In Norway, use of thiazide diuretics has declined, but use of loop-diuretics has remained unchanged. Loop-diuretics are still first-line drugs in cases of heart failure. The author discusses treatment of patients resistant to conventional doses of diuretics, and the causes of the resistance. Since furosemide and bumetanide may have very different effects and side effects, both are needed as treatment alternatives.

摘要

袢利尿剂抑制髓袢升支粗段的Na+/K+/2Cl(-)共转运系统,是利尿作用最强的利尿剂。它们还会增加前列腺素的生成,静脉给药时可降低肺毛细血管压力。本文综述了袢利尿剂的临床疗效和副作用。在挪威,噻嗪类利尿剂的使用有所下降,但袢利尿剂的使用保持不变。在心力衰竭病例中,袢利尿剂仍是一线药物。作者讨论了对常规剂量利尿剂耐药患者的治疗方法以及耐药原因。由于呋塞米和布美他尼可能具有非常不同的作用和副作用,因此两者都需要作为治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验